SCHEMBL23218036

SCHEMBL23218036

CCOC(=O)Cc1ccccc1NC(=O)c1coc2ccc(Br)cc12

nearest known ligand 0.47

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
MAPT P10636 4/20 0.47
THRB P10828 1/20 0.47
ALDH1A1 P00352 2/20 0.44
HTT P42858 2/20 0.44
MAOB P27338 8/20 0.43
SMN1; SMN2 Q16637 3/20 0.42
KDM4E B2RXH2 2/20 0.42
MAPK1 P28482 1/20 0.42
POLB P06746 2/20 0.40
GAA P10253 2/20 0.40
RECQL P46063 1/20 0.40
ADORA3 P0DMS8 1/20 0.39
TSHR P16473 1/20 0.39
NPSR1 Q6W5P4 1/20 0.39
HSD17B10 Q99714 1/20 0.39
RXFP1 Q9HBX9 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31425808 0.79 MEN1 (0.47) MAPTTHRBALDH1A1HTTSMN1; SMN2
SCHEMBL8175604 0.79 MEN1 (0.47) MAPTTHRBALDH1A1HTTSMN1; SMN2
Methylene Chloride SCHEMBL8520941 0.76 MEN1 (0.45) MAPTTHRBALDH1A1HTTSMN1; SMN2
SCHEMBL73880 0.76 MAOB (0.47) MAPTMAOBSMN1; SMN2GAA
SCHEMBL23218949 0.76 TBXAS1 (0.41) MAPTALDH1A1HTTMAOBPOLB
SCHEMBL9844024 0.74 MAOB (0.57) ALDH1A1HTTMAOBSMN1; SMN2MAPK1
SCHEMBL31393683 0.74 MAOB (0.57) ALDH1A1HTTMAOBSMN1; SMN2MAPK1
SCHEMBL23218161 0.74 TBXAS1 (0.45) MAPTALDH1A1HTTMAOBPOLB
SCHEMBL72819 0.74 MAOB (0.45) MAPTMAOBSMN1; SMN2GAA
SCHEMBL21438189 0.74 TDP1 (0.41) MAPTALDH1A1HTTSMN1; SMN2KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12558341-B2 Oral complement factor D inhibitors BIOCRYST PHARMACEUTICALS, INC. (US) 2026-02-24 US disclosed
US-20250186391-A1 ORAL COMPLEMENT FACTOR D INHIBITORS WILMINGTON TRUST, NATIONAL ASSOCIATION 2025-06-12 US disclosed
EP-4041238-A1 ORAL COMPLEMENT FACTOR D INHIBITORS Biocryst Pharmaceuticals, Inc. (US) 2022-08-17 EP disclosed
CN-114502168-A Oral complement factor D inhibitors 拜奥克里斯特制药公司 2022-05-13 CN disclosed
WO-2021072198-A1 ORAL COMPLEMENT FACTOR D INHIBITORS BIOCRYST PHARMACEUTICALS, INC. (US) 2021-04-15 WO disclosed
WO-2021072198-A1 ORAL COMPLEMENT FACTOR D INHIBITORS BIOCRYST PHARMACEUTICALS, INC. (US) 2021-04-15 WO disclosed
US-20160361275-A1 SUBSTITUTED PHENETHYLAMINES WITH SEROTONINERGIC AND/OR NOREPINEPHRINERGIC ACTIVITY ACADIA PHARMACEUTICALS INC. 2016-12-15 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160361275-A1 SUBSTITUTED PHENETHYLAMINES WITH SEROTONINERGIC AND/OR NOREPINEPHRINERGIC ACTIVITY SLC6A4, HTR4, GPR34 MAPT 234/4885THRB 332/4885ALDH1A1 3075/4885
US-12558341-B2 Oral complement factor D inhibitors CFD, CFH, CFB MAPT 4793/4885THRB 2013/4885ALDH1A1 2667/4885
US-20250186391-A1 ORAL COMPLEMENT FACTOR D INHIBITORS CFD, CFH, CFB MAPT 3561/4885THRB 3892/4885ALDH1A1 3142/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.